# Pistachio Cholesterol Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/pistachio-cholesterol-randomized-trial-evidence-review
Category: evidence-review
Summary: Pistachio Cholesterol Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are 
Last reviewed: 2026-07-09
Reviewed by: Migaku Evidence Review
# Pistachio Cholesterol Randomized Trial: What the Evidence Says

## Quick Answer

Pistachio Cholesterol Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 randomized trial.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Nut consumption in chronic kidney disease: a systematic review | systematic review | 1 | 2025-11-10 | 10.3389/fnut.2025.1659516 |
| Rationale, Design, and Participant Baseline Characteristics of a Parallel Randomized Trial of the Effect of Replacing SSBs with Cow’s Milk Versus Soymilk on Intrahepatocellular Lipid and Other Cardiometabolic Risk Factors in Adults with Obesity Who Consume Sugar-Sweetened Beverages: The Soy Treatment Evaluation for Metabolic health (STEM) Trial | randomized trial | 2 | 2026-03-24 | 10.3390/nu18071026 |

## What The Sources Report

- Traditional risk factors for CKD development and progression include diabetes, hypertension, and obesity. [Lazzarin Taline (2025); evidence level 1]
- In particular, inflammation and oxidative stress contribute to vascular injury, endothelial dysfunction, and accelerated atherosclerosis, which markedly increase the risk of cardiovascular morbidity and mortality in this population. [Lazzarin Taline (2025); evidence level 1]
- Abdominal obesity, defined by excess visceral fat accumulation, is a key driver of cardiometabolic risk and is central to the global epidemics of obesity and type 2 diabetes. [Erlich Madeline N. (2026); evidence level 2]
- In this context, diets high in free sugars have been consistently implicated in the development of liver fat and in contributing substantially to abdominal obesity, prompting global health authorities to recommend limiting free sugars to less than 10% of total energy intake. [Erlich Madeline N. (2026); evidence level 2]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For pistachio cholesterol randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Lazzarin Taline (2025). Nut consumption in chronic kidney disease: a systematic review. DOI: 10.3389/fnut.2025.1659516. PMCID: PMC12642863. PMID: 41293182. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12642863/
- Erlich Madeline N. (2026). Rationale, Design, and Participant Baseline Characteristics of a Parallel Randomized Trial of the Effect of Replacing SSBs with Cow’s Milk Versus Soymilk on Intrahepatocellular Lipid and Other Cardiometabolic Risk Factors in Adults with Obesity Who Consume Sugar-Sweetened Beverages: The Soy Treatment Evaluation for Metabolic health (STEM) Trial. DOI: 10.3390/nu18071026. PMCID: PMC13074930. PMID: 41978078. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13074930/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.